US Stock MarketDetailed Quotes

VERV Verve Therapeutics

Watchlist

4.980
+0.020+0.40%

Close Sep 27 16:00 ET

4.980
0.0000.00%

Post 20:02 ET

421.43MMarket Cap-1922P/E (TTM)

Verve Therapeutics Stock Forum

2017x

Sep 20 08:54

$Verve Therapeutics (VERV.US)$ annnnnnnndd its gone

2017x

Sep 20 06:55

$Verve Therapeutics (VERV.US)$ premarket looking good

Hammer Man

Jun 28 15:25

$Verve Therapeutics (VERV.US)$ 👀

MARKET-TEST-DUMMY

Jun 11 05:07

Still Basting

$Verve Therapeutics (VERV.US)$

frankinglily

May 14 03:38

How does the biotech ecosystem support advancements in personalized medicine & genomics?
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...

ClydePeternuts

May 14 02:16

Cathie Wood's Ark Invest Buys $18M In Shopify Stock Amid Price Dip, Sells Shares In Bitcoin Bull Jack Dorsey's Block Inc

On Monday, Cathie Wood’ s Ark Invest made some significant trades, the most notable being the purchase of $Shopify (SHOP.US)$ and the sale od $Block (SQ.US)$
The Shopify Trade
$ARK Fintech Innovation ETF (ARKF.US)$ $ARK Innovation ETF (ARKK.US)$ and $ARK Next Generation Internet ETF (ARKW.US)$ Purchased a total of 313,¢3 shares of Shopify on Monday. This move came after the company ...

Trytosaveabit

May 7 06:20

Update

$Verve Therapeutics (VERV.US)$ Verve Therapeutics Announces Dosing Of First Patient In Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

y f ii

Apr 2 09:23

$Verve Therapeutics (VERV.US)$ 6

Trytosaveabit

Apr 2 06:13

Read the whole PR! But reason for fall

$Verve Therapeutics (VERV.US)$ However, the sixth participant treated in the 0.45 mg/kg cohort experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase (ALT) as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia within the first four days after dosing. The participant did not experience any bleeding or other symptoms related to the laboratory abnormalities, and the abnormalities resolved fully within a few ...

Moomoo AI

Mar 3 07:23

Analysts are optimistic about Verve Therapeutics, predicting reduced losses this year, indicating a move towards profitability. Despite expected slower revenue growth, it's still anticipated to outpace the industry. However, concerns like dilutive stock issuance over the past year persist.

Rainbows and Unicorns: Verve Therapeutics, Inc. (NASDAQ:VERV) Analysts Just Became A Lot More Optimistic

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data